{"prompt": "['2017N323364_0', 'CONFIDENTIAL', '2019N398531_00', '207626', '12.8.', 'Appendix 8: Clinical Laboratory Tests', 'All protocol required laboratory assessments (haematology, clinical chemistry', 'and urinalysis) must be conducted in accordance with the Laboratory Manual,', 'and Protocol SoA (Section 2). Laboratory requisition forms must be completed', 'and samples must be clearly labelled with the participant number, protocol', 'number, site/centre number, and visit date. Details for the preparation and', 'shipment of samples will be provided by the laboratory and are detailed in the', 'Laboratory Manual. Reference for all safety parameters will be provided to the', 'site by the laboratory responsible for the assessments.', 'All blood samples which will be taken pre-dose, will be sent to a central', 'laboratory for analysis (details provided in the Laboratory Manual). Standard', 'reference ranges will be used.', 'If additional non-protocol specified laboratory assessments are performed at the', \"institution's local laboratory and result in a change in participant management or\", 'are considered clinically significant by the Investigator (e.g., SAE or AE or dose', 'modification) the results must be recorded in the eCRF.', 'Refer to the Laboratory Manual for appropriate processing and handling of', 'samples to avoid duplicate and/or additional blood draws.', 'Protocol-specific requirements for inclusion or exclusion of participants are', 'detailed in Section 6.1 of the protocol.', 'Additional tests may be performed at any time during the study as determined', 'necessary by the Investigator or required by local regulations.', '102']['2017N323364_0', 'CONFIDENTIAL', '2019N398531_00', '207626', 'Table 6', 'Protocol-Required Safety Laboratory Assessments', 'Laboratory', 'Parameters', 'Assessments', 'Hematology', 'Platelet Count', 'RBC Indices:', 'WBC count with', 'RBC Count', 'Mean Corpuscular', 'Differential:', 'Hemoglobin', 'Volume (MCV)', 'Neutrophils', 'Hematocrit', 'Mean Corpuscular', 'Lymphocytes', 'Hemoglobin (MCH)', 'Monocytes', 'Eosinophils', 'Basophils', 'Clinical', 'Blood Urea', 'Potassium', 'Aspartate', 'Total and direct', 'Chemistry1', 'Nitrogen (BUN)', 'Aminotransferase', 'bilirubin', '(AST)/Serum', 'Glutamic-', 'Oxaloacetic', 'Transaminase', '(SGOT)', 'Creatinine', 'Sodium', 'Alanine', 'Total Protein', 'Aminotransferase', '(ALT)/ Serum', 'Glutamic-Pyruvic', 'Transaminase', '(SGPT)', 'Glucose', 'Calcium', 'Alkaline', '[nonfasting]', 'phosphatase', 'Routine', 'Urinalysis', 'Specific gravity', 'pH, glucose, protein, blood, ketones, by dipstick', 'Microscopic examination (if blood or protein is abnormal)', 'Other', 'Screening', 'Follicle-stimulating hormone and estradiol (as needed in women of non-', 'Tests', 'childbearing potential only)', 'Serum/urine human chorionic gonadotropin (hCG) pregnancy test (as', 'needed for women of childbearing potential\u00b2\u00b2', 'The results of each test must be entered into the eCRF.', 'NOTES', '1. Details of liver chemistry stopping criteria and required actions and follow-up assessments after liver stopping or', 'monitoring event are given in Section 8.1 and Appendix 7 All events of ALT >3 x upper limit of normal (ULN) and', 'bilirubin >2 x ULN (>35 % direct bilirubin) or ALT >3 x ULN and international normalized ratio (INR) >1.5, if INR', \"measured, which may indicate severe liver injury (possible Hy's Law), must be reported as an SAE (excluding\", 'studies of hepatic impairment or cirrhosis).', '2. Local urine testing will be standard for the protocol unless serum testing is required by local regulation or IRB/IEC.', '103']['2017N323364_0', 'CONFIDENTIAL', '2019N398531_00', '207626', '12.9.', 'Appendix 9: Genetics', 'USE/ANALYSIS OF DNA', \"Genetic variation may impact a participant's response to therapy, susceptibility,\", 'severity and progression of disease. Variable response to therapy may be due to', 'genetic determinants that impact drug absorption, distribution, metabolism, and', 'excretion; mechanism of action of the drug; disease etiology; and/or molecular', 'subtype of the disease being treated. Therefore, where local regulations and IRB/IEC', 'allow, a 6 mL blood sample will be collected for DNA analysis.', 'DNA samples may be used for research related to study treatment or COPD and', 'related diseases. They may also be used to develop tests/assays including diagnostic', 'tests) related to study treatment or study treatments of this drug class and indication.', 'Genetic research may consist of the analysis of one or more candidate genes', '(including but not limited to: PIK3CD, PIK3CA, IL10, CHRNA3, CHRNA5, DNAH5,', 'SUMF1, and CELSRI) or the analysis of genetic markers throughout the genome [or', 'analysis of the entire genome] (as appropriate)', 'The samples may be analyzed as part of a multi-study assessment of genetic factors', 'involved in the response to study treatment or study treatments of this class. The', 'results of genetic analyses may be reported in the clinical study report or in a', 'separate study summary.', 'In the event of DNA extraction failure, a replacement genetic blood sample may be', 'requested from the participant. Signed informed consent will be required to obtain a', 'replacement sample unless it was included in the original consent.', 'The sponsor will store the DNA samples in a secure storage space with adequate', 'measures to protect confidentiality.', 'The samples will be retained while research on study treatment (or study treatments', 'of this class) or indication continues but no longer than 15 years after the last', 'participant last visit or other period as per local requirements.', 'Withdraw Process: If a participant withdraws consent, the Investigator must', 'complete the Genetic Sample Destruction Request Form, which will be provided to', 'the site in the Investigator Site File.', 'Destruction Process: After the specified storage period of 15 years or on', 'withdrawal of consent, samples will be destroyed by incineration. Samples that are', 'sent for testing to vendors are returned or destroyed as part of the formal agreement', 'and a full record of chain of custody is maintained. A laboratory information', 'management system (LIMS) is used to track and identify samples for destruction.', '104']\n\n###\n\n", "completion": "END"}